Eli Lilly became the first pharmaceutical company to reach a US$1 trillion market capitalization in 2024.
Eli Lilly crossed the threshold in August 2024 as investors responded to strong demand and optimistic forecasts for its diabetes and obesity medicines. Its incretin-based treatments, including Mounjaro and Zepbound, became major drivers of expectations for future revenue.
The company’s market value reflected anticipated sales and growth, not a single year of recorded revenue. Drug companies can receive very high valuations when investors expect a successful medicine to serve a large patient population for many years.
This milestone is distinct from Novo Nordisk’s earlier rise as a leading obesity-drug manufacturer and from the much older market-cap records of technology companies. Eli Lilly’s achievement specifically concerned a pharmaceutical company crossing US$1 trillion in market capitalization.